C. butyricum Combined With Resmetirom Provides Therapeutic Benefits in MASH Associated With Gut–Liver–Brain Axis Modulation
Liver International · 2026-11 · 46 (11)
DOI: 10.1111/liv.70905 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 08.10.2026. Verfasst von Kaige Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China. Hauptthemen laut MEDLINE: Liver, Gastrointestinal Microbiome, Clostridium butyricum, Brain-Gut Axis. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background and Aims Resmetirom has emerged as a major advance in MASH pharmacotherapy as the first approved liver‐targeted THR‐β agonist; however, variable therapeutic efficacy and adverse responses may limit its clinical benefits. This study investigated whether C. butyricum could provide additional therapeutic benefits when combined with resmetirom and attenuate nausea/vomiting‐like responses in association with changes across the gut–liver–brain axis.
Methods
In this study, we established a high‐fat diet‐induced MASH mouse model and administered C. butyricum , resmetirom, or their combination. Comprehensive biochemical, histological, molecular, 16S rRNA sequencing‐based microbiome profiling, and gut–brain axis‐related analyses were performed to evaluate the effects of combination therapy on hepatic metabolism, inflammation, fibrosis, intestinal barrier integrity, gut microbiota remodelling, microbial metabolites, and resmetirom‐associated adverse responses.
Results
Combined treatment with C. butyricum and resmetirom produced additional therapeutic benefits compared with either monotherapy, markedly improving hepatic steatosis, lipid accumulation, insulin resistance, inflammation, oxidative stress, and fibrosis in MASH mice. At the molecular level, combination treatment was associated with increased hepatic THR‐β expression and coordinated changes in AMPK‐related lipid metabolism, NRF2/HO‐1 antioxidant, and TLR4/MyD88/NF‐κB inflammatory markers. Furthermore, combination therapy restored intestinal barrier integrity, alleviated MASH‐associated gut microbial dysbiosis, increased beneficial bacterial taxa, and increased faecal butyrate levels. Notably, C. butyricum attenuated resmetirom‐induced nausea/vomiting‐like responses, accompanied by reduced colonic and cerebral 5‐HT/SP signalling, decreased brain Htr3a and Tacr1 mRNA expression, and suppressed neuronal FOS activation. Faecal butyrate levels were inversely associated with hepatic lipid burden and brain 5‐HT/SP levels.
Conclusions
C. butyricum combined with resmetirom provides additional therapeutic benefits and attenuates nausea/vomiting‐like responses in MASH, accompanied by coordinated changes across the gut–liver–brain axis. This combination strategy provides a potential microbiota‐based adjunctive approach for optimizing the therapeutic benefits of resmetirom in MASH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
- Jiangxi Province Key Laboratory of Bioengineering Drugs, School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
- National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
- Department of Infectious Diseases, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
- Queen Mary School, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
- Huan Kui Academy, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
ORCID-Profile: Kaige Zhang, Yuyu Zeng, Jianhua Wu, Tingtao Chen
Zitieren
APA
Zhang, K., Zeng, Y., Wu, J., Liu, Y., Zhang, Y., Liao, Z., Li, Y., Zhong, J., Xie, Z., & Chen, T. (2026). C. butyricum Combined With Resmetirom Provides Therapeutic Benefits in MASH Associated With Gut–Liver–Brain Axis Modulation. Liver International, 46(11). https://doi.org/10.1111/liv.70905
Vancouver
Zhang K, Zeng Y, Wu J, Liu Y, Zhang Y, Liao Z, et al. C. butyricum Combined With Resmetirom Provides Therapeutic Benefits in MASH Associated With Gut–Liver–Brain Axis Modulation. Liver International. 2026;46(11). doi:10.1111/liv.70905
BibTeX
@article{Zhang2026,
author = {Zhang, Kaige and Zeng, Yuyu and Wu, Jianhua and Liu, Yicheng and Zhang, Yue and Liao, Zhaohui and Li, Yangyang and Zhong, Junqiang and Xie, Zhengyuan and Chen, Tingtao},
title = {C. butyricum Combined With Resmetirom Provides Therapeutic Benefits in MASH Associated With Gut–Liver–Brain Axis Modulation},
journal = {Liver International},
year = {2026},
volume = {46},
number = {11},
doi = {10.1111/liv.70905}
}
EUVIMED